ABS, American Brachytherapy Society; Brachytherapy; CCAFU, Cancer Committee of the French Association of Urology; CT, computerized tomography; CTCAE, common terminology criteria for adverse events; CTV, clinical target volume; Conservative treatment; DFS, disease-free survival; DNR, dose non-homogenity ratio; EAU, European Association of Urology; EBRT, external beam radiotherapy; EQD2, equivalent dose in 2Gy fractions; GC-SFRO, Groupe Curiethérapie/Société Française de Radiothérapie Oncologique; GEC-ESTRO, Groupe Européen de Curiethérapie/European Society for Therapeutic Radiation and Oncology; HDB, high-dose brachytherapy; IIEF, international index of erectile function; IPSS, international prostate symptom score; LC, local control; LDR, low-dose rate; MDFS, metastatic disease-free survival; MFU, median follow-up; MHB, multicatheter interstitial high-dose rate brachytherapy; MMS, Mohs micrographic surgery; MRI, magnetic resonance imaging; NCCN, national comprehensive cancer network; OS, overall survival; PDR, pulse-dose rate; PET, positron emission tomography; PP, penile preservation; Penectomy; Penile cancer; RC, regional control; SCC, squamous cell carcinoma; SFRO, Société Française de Radiothérapie Oncologique; SS, specific survival; TNM, tumor node metastasis